<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/43BEDA5F-E824-412D-A4AC-ED7F1139F5CC"><gtr:id>43BEDA5F-E824-412D-A4AC-ED7F1139F5CC</gtr:id><gtr:name>University of Turin</gtr:name><gtr:address><gtr:line1>Via Giuseppe Verdi 8</gtr:line1><gtr:postCode>I-10124</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/B3964FBA-1A89-4A74-A173-7894738ED2F1"><gtr:id>B3964FBA-1A89-4A74-A173-7894738ED2F1</gtr:id><gtr:name>Johnson Matthey Plc</gtr:name><gtr:address><gtr:line1>40-42 Hatton Garden</gtr:line1><gtr:postCode>EC1N 8EE</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A3BC8C35-5491-4D82-B2EA-5C6F4A57BC0B"><gtr:id>A3BC8C35-5491-4D82-B2EA-5C6F4A57BC0B</gtr:id><gtr:name>Istituto Nazionale di Fisica Nucleare</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/50E55759-0E37-48B7-9DCA-BB9F3CCC364A"><gtr:id>50E55759-0E37-48B7-9DCA-BB9F3CCC364A</gtr:id><gtr:name>Joseph Fourier University</gtr:name><gtr:address><gtr:line1>CS40700</gtr:line1><gtr:postCode>F-38058</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4260A3C6-7987-4CE4-B5B5-1D3D3FA25E4E"><gtr:id>4260A3C6-7987-4CE4-B5B5-1D3D3FA25E4E</gtr:id><gtr:name>European Synchrotron Radiation Facility (ESRF)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Clinical and Experimental Medicine</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/43BEDA5F-E824-412D-A4AC-ED7F1139F5CC"><gtr:id>43BEDA5F-E824-412D-A4AC-ED7F1139F5CC</gtr:id><gtr:name>University of Turin</gtr:name><gtr:address><gtr:line1>Via Giuseppe Verdi 8</gtr:line1><gtr:postCode>I-10124</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B3964FBA-1A89-4A74-A173-7894738ED2F1"><gtr:id>B3964FBA-1A89-4A74-A173-7894738ED2F1</gtr:id><gtr:name>Johnson Matthey Plc</gtr:name><gtr:address><gtr:line1>40-42 Hatton Garden</gtr:line1><gtr:postCode>EC1N 8EE</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A3BC8C35-5491-4D82-B2EA-5C6F4A57BC0B"><gtr:id>A3BC8C35-5491-4D82-B2EA-5C6F4A57BC0B</gtr:id><gtr:name>Istituto Nazionale di Fisica Nucleare</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/50E55759-0E37-48B7-9DCA-BB9F3CCC364A"><gtr:id>50E55759-0E37-48B7-9DCA-BB9F3CCC364A</gtr:id><gtr:name>Joseph Fourier University</gtr:name><gtr:address><gtr:line1>CS40700</gtr:line1><gtr:postCode>F-38058</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4260A3C6-7987-4CE4-B5B5-1D3D3FA25E4E"><gtr:id>4260A3C6-7987-4CE4-B5B5-1D3D3FA25E4E</gtr:id><gtr:name>European Synchrotron Radiation Facility (ESRF)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D137D502-3EE1-4B16-B645-A5BB019405E5"><gtr:id>D137D502-3EE1-4B16-B645-A5BB019405E5</gtr:id><gtr:firstName>Zoe</gtr:firstName><gtr:surname>Pikramenou</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/96766906-8EC7-4398-B0EB-CFD68318E626"><gtr:id>96766906-8EC7-4398-B0EB-CFD68318E626</gtr:id><gtr:firstName>Boris</gtr:firstName><gtr:surname>Kysela</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0900034"><gtr:id>BBB31DF3-7A4E-4159-BA20-663357FF2701</gtr:id><gtr:title>Imaging, Nuclear Targeting and Modulation of DNA Damage Responses by Polyfunctionalized Nanoparticles in Tumour Cells</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900034</gtr:grantReference><gtr:abstractText>Looking small thinking big - what is nanotechnology? One of the definitions of nanotechnology describes it as:
?The design, characterization, production, and application of structures, devices, and systems by controlled manipulation of size and shape at the nanometer scale (atomic, molecular, and macromolecular scale) that produces structures, devices, and systems with at least one novel/superior characteristic or property.? There are quite a few other definitions as well and some confusion about what nanotechnology really means. In simple terms we can say that nanotechnology is a science of small bits of man-made materials that are about thousand to ten thousand times smaller than the thickness of human hair. The ?man-made? is important because otherwise all natural molecules and material particles would have to be included. What is also important is that these small bits of material can gain very unusual and unique properties, not found in the bigger pieces. Our research is trying to exploit these new qualities of the old materials to improve the health prospects of cancer patients. We shall change the surface properties of tiny gold and platinum spheres made in our laboratory in such a way that will allow them to find,enter and mark cancer cells so X-rays machines and other scanners used in diagnostic procedures can better see them. They will also have the ability to amplify the effects of radiation used for treating tumours and to knock-down cancer cell defences against it. Does it mean then that small is always beautiful? Not really. As much as these new tiny nanoparticles can gain the unique properties that are desirable and useful, in the same way their new qualities can be unexpectedly harmful. We shall investigate these potentially harmful effects in normal human cells, so we can select the particles that would have the most potent effects on the cancer cells whilst being the least harmful to surrounding normal cells.</gtr:abstractText><gtr:technicalSummary>Nanotechnology represents the area of science focused on the manipulation of atoms and molecules that leads to new structures in the nanometer scale range. These structures often gain unique and unexpected properties. In cancer nanotechnology the focus is on development of nanoscale devices that can diagnose, deliver therapeutic agents, and monitor cancer treatment progress. The early and efficient detection of small cancer (and, possibly, pre-cancerous) lesions remains the most important goal of diagnostic imaging. Increasing target selectivity is critical for nanovectors acting as carriers for both imaging and therapeutic payloads. Ideally, any imaging or therapeutic system would be exclusively targeted to the tumour cell clusters or tumour cell vasculature, preferably with the ability to do so at early stages of malignant transformation. Effective as all the individual approaches might be by themselves, we believe that the greatest gains will be achieved by their synergistic combination. The past decades had seen an outstanding progress in our understanding of the fundamental cancer biology, but this development was not accompanied by comparable advances in the clinic. For example the radiation therapy in humans benefited much more from the technical progress and computerization rather than from knowledge-based manipulation of the biological responses of cancer cells to therapeutic radiation. In this proposal, we introduce the development of novel, multi-functional nanocariers that would translate our understanding of DNA damage responses and new nano-imaging technologies into more efficient ways of diagnosis and treatment of cancer. Our strategy is to design and test multifunctional gold and platinum nanoparticles with following desired properties:
 
? Potential for in vivo imaging of targeted tumour cells 
? Increased target selectivity for cancer cells 
? Capability to increase the dose efficacy of radiotherapy and ability to inhibit DNA damage responses in targeted cells

In line with the MCMB Committee?s recommendations regarding our previous, more extensive, application, this is a proof-of-principle streamlined research proposal that will focus on the development of prototype polyfunctional nanoparticles with selected properties followed by testing predicted specificity of biological responses in vitro only.</gtr:technicalSummary><gtr:fund><gtr:end>2011-06-02</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-08-03</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>337313</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johnson Matthey</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with the Industrial Partner</gtr:description><gtr:id>A89F8267-BED0-4FEB-9823-20FC8F85F1F8</gtr:id><gtr:impact>A large joint project grant application under MICA scheme</gtr:impact><gtr:partnerContribution>access to the facilities, intelectual input to the project development</gtr:partnerContribution><gtr:piContribution>Project development, access to the facilities,</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Joseph Fourier University</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Grenoble Institute of Neuroscience INSERM (U836)</gtr:department><gtr:description>International collaboration</gtr:description><gtr:id>7C704298-F759-4DBA-90EC-447EFACC3C5E</gtr:id><gtr:impact>joint grant application</gtr:impact><gtr:partnerContribution>access to facilities, intelectual input</gtr:partnerContribution><gtr:piContribution>Access to facilities, intelectual input</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Turin (Universit? degli Studi di Torino UNITO)</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Intenational collaboration and Horizon 2020 proposal submitted</gtr:description><gtr:id>909AAF91-D7F7-47CB-A31D-F952D63FE305</gtr:id><gtr:impact>Multidisciplinary proposal to Horizon 2020 programme:
Title of Proposal: Neutron Capture Therapy (NCT): a non-conventional radiotherapy for the treatment of Malignant Pleural Mesothelioma based on a theranostic approach using Gd/B multimodal probes.
Acronym: MesoTHER
Physics
Chemistry
Medicine 
Biology</gtr:impact><gtr:partnerContribution>Project proposal submitted for Horizon 2020 programme</gtr:partnerContribution><gtr:piContribution>Project proposal for Horizin 2020 programme</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Synchrotron Radiation Facility (ESRF)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Nanoimaging Group ESRF</gtr:department><gtr:description>International collaboration</gtr:description><gtr:id>0F69BA3D-E443-4C83-A4E6-F7507D70832F</gtr:id><gtr:impact>20879836
Two successful project grant applications to ESRF

A new research grant application to MRC submitted

Our nanoparticle imaging work at European Synchrotron Research Facility (ESRF) had been chosen as one of the strategic highlights for the year 2010: www.esrf.eu/UsersAndScience/Publications/Highlights/2010
and selected as strategic future priority.

The</gtr:impact><gtr:partnerContribution>research program extension</gtr:partnerContribution><gtr:piContribution>training of staff, intelectual input</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Synchrotron Radiation Facility (ESRF)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Nanoimaging Group ESRF</gtr:department><gtr:description>The Brain Tumour Charity Quest for Cures Initiative Programme grant application</gtr:description><gtr:id>CEFF2FC9-0F12-4F95-82BB-7FA63D0CDD05</gtr:id><gtr:impact>programme grant application</gtr:impact><gtr:partnerContribution>Co-applicants</gtr:partnerContribution><gtr:piContribution>Leading applicant and coordinator</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Birmingham NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with a partner in NHS</gtr:description><gtr:id>C19DA072-4F0E-4DCE-B90F-F2CD09D850EB</gtr:id><gtr:impact>joint grant application submitted</gtr:impact><gtr:partnerContribution>Project development, joint grant applications</gtr:partnerContribution><gtr:piContribution>Access to facilities, poject development</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Istituto Nazionale di Fisica Nucleare</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>International consortium for Horizon 2020 programme</gtr:description><gtr:id>BA257CCB-0405-48AB-A63D-F3626978B204</gtr:id><gtr:impact>Horizon 2020 proposal submitted:
Title: Cell-targeted radiotherapy with accelerator produced neutrons
Acronym: RACER - Radio frequency ACcelerator-based facility for cancER
Medicine
Physics
Chemistry
Biology</gtr:impact><gtr:partnerContribution>Multidisciplinary Horizon 2020 project proposal</gtr:partnerContribution><gtr:piContribution>Horizon 2020 project proposal</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Seminar</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>CEB7B53E-BB0C-41F2-80D9-56B9A9986FCC</gtr:id><gtr:impact>A talk had been delivered to a private sector company interested in collaboration

A joint grant application under the MICA scheme with this industrial partner</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>37323</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grant/Birmingham Children's Hospital Research Fund</gtr:description><gtr:end>2010-03-02</gtr:end><gtr:fundingOrg>European Synchrotron Radiation Facility (ESRF)</gtr:fundingOrg><gtr:id>FA53113A-FA08-40E8-9005-E84206FDB31C</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>44788</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ESRF project grant</gtr:description><gtr:end>2011-04-02</gtr:end><gtr:fundingOrg>European Synchrotron Radiation Facility (ESRF)</gtr:fundingOrg><gtr:id>162FA998-EF07-4AD4-882A-3D43BBEB213D</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>37323</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ESRF Project grant</gtr:description><gtr:end>2010-05-02</gtr:end><gtr:fundingOrg>European Synchrotron Radiation Facility (ESRF)</gtr:fundingOrg><gtr:id>E9107795-E21B-4A3F-988C-5F94235DF560</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50461</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grant/Birmingham Children's Hospital Research Fund</gtr:description><gtr:end>2010-03-02</gtr:end><gtr:fundingOrg>Queen Elizabeth Hospital Birmingham Charity (QEHB)</gtr:fundingOrg><gtr:id>9C8D74C5-AE39-456F-BBAE-673848F6327C</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75550</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Follow on Fund</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>771F3D76-3D85-4CD5-8E2B-2AC713B24D88</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Precious metal based functionalized nanoparticles for cancer treatment and imaging</gtr:description><gtr:id>7543ACB2-8FF7-4A44-BC01-3941DD44B625</gtr:id><gtr:impact>Commercial licensing under negotiations</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2013/179014</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Targeted nanoparticles for cancer imaging and therapy</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in the ESRF future developments review</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>E3DAAF01-7D5C-495B-B8CC-219C84250F51</gtr:id><gtr:impact>The nanoimaging program has been identified as a priority in the future planned expansion of ESRF</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A unique method had been developed for the intracelular imaging of internalized nanoparticles using hard X-ray probe</gtr:description><gtr:id>0F76773F-D9B4-49C2-9D2A-43D05CD1F907</gtr:id><gtr:impact>A novel method in the development of nanovectors for use in medicine and biotechnology</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Synchrotron X-ray imaging of nanoparticles in cells</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/184ED36C-D4ED-41EB-8AB9-A24DCAB5B634"><gtr:id>184ED36C-D4ED-41EB-8AB9-A24DCAB5B634</gtr:id><gtr:title>Mutations in the NHEJ component XRCC4 cause primordial dwarfism.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e6892d496fb7cfc02f1e5c03661cddd5"><gtr:id>e6892d496fb7cfc02f1e5c03661cddd5</gtr:id><gtr:otherNames>Murray JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/47D3365F-0390-4F9F-B57C-C0AD96F73227"><gtr:id>47D3365F-0390-4F9F-B57C-C0AD96F73227</gtr:id><gtr:title>Issues surrounding standard cytotoxicity testing for assessing activity of non-covalent DNA-binding metallo-drugs.</gtr:title><gtr:parentPublicationTitle>Dalton transactions (Cambridge, England : 2003)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c50fc002e47b020045085ee9a7fefd73"><gtr:id>c50fc002e47b020045085ee9a7fefd73</gtr:id><gtr:otherNames>Pope AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1477-9226</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/50AAD00C-A82F-4ECF-B3D7-1B37CFA8E986"><gtr:id>50AAD00C-A82F-4ECF-B3D7-1B37CFA8E986</gtr:id><gtr:title>Intracellular synchrotron nanoimaging and DNA damage/genotoxicity screening of novel lanthanide-coated nanovectors.</gtr:title><gtr:parentPublicationTitle>Nanomedicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6c596083cef76b223fc8de20413688e8"><gtr:id>6c596083cef76b223fc8de20413688e8</gtr:id><gtr:otherNames>Lewis DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1743-5889</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900034</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8EA3EC93-8E9C-482F-8121-C6C8413D9B6D</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.3  Chemical and physical sciences</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>